A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy

Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Kasivisvanathan, 2017, A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol, BMJ Open, 7, e017863, 10.1136/bmjopen-2017-017863 Roobol, 2012, Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators, Eur Urol, 61, 577, 10.1016/j.eururo.2011.11.012 Alberts, 2019, Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators, Eur Urol, 75, 310, 10.1016/j.eururo.2018.07.031 Radtke, 2017, Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer-patient-tailored risk stratification can reduce unnecessary biopsies, Eur Urol, 72, 888, 10.1016/j.eururo.2017.03.039 Lundon, 2015, Prostate cancer risk assessment tools in an unscreened population, World J Urol, 33, 827, 10.1007/s00345-014-1365-7 Wei, 2021, Clash of the calculators: external validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy, BJUI Compass, 2, 194, 10.1002/bco2.58 van Leeuwen, 2017, A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy, BJU Int, 120, 774, 10.1111/bju.13814 Kalapara, 2020, Detection and localisation of primary prostate cancer using 68gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology, BJU Int, 126, 83, 10.1111/bju.14858 Kalapara, 2022, Combined utility of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography and multiparametric magnetic resonance imaging in predicting prostate biopsy pathology, Eur Urol Oncol, 5, 314, 10.1016/j.euo.2021.02.006 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Ong, 2022, PSMA PET-CT imaging predicts treatment progression in men with biochemically recurrent prostate cancer—a prospective study of men with 3 year follow up, Cancers, 14, 2717, 10.3390/cancers14112717 Sonni, 2022, J Nucl Med, 63, 847, 10.2967/jnumed.121.262398 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 de Feria Cardet, 2021, Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial, Eur Urol, 79, 413, 10.1016/j.eururo.2020.11.043 Fendler, 2019, Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial, JAMA Oncol, 5, 856, 10.1001/jamaoncol.2019.0096 Morris, 2021, Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study, Clin Cancer Res, 27, 3674, 10.1158/1078-0432.CCR-20-4573 Pienta, 2021, A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY), J Urol, 206, 52, 10.1097/JU.0000000000001698 O’Brien, 2022, PSMA PET-CT funding grants free access to superior staging for Australian men with prostate cancer, BJU Int, 10.1111/bju.15773 Donato, 2019, Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology, Eur J Nucl Med Mol Imaging, 46, 20, 10.1007/s00259-018-4160-7 Emmett, 2021, The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study, Eur Urol, 80, 682, 10.1016/j.eururo.2021.08.002 Amin, 2020, BJU Int, 125, 515, 10.1111/bju.14999 Neumann, 2017, EFS: an ensemble feature selection tool implemented as R-package and web-application, BioData Min, 10, 21, 10.1186/s13040-017-0142-8 Polikar, 2006, Ensemble based systems in decision making, IEEE Circuits Syst Mag, 6, 21, 10.1109/MCAS.2006.1688199 R Core Team, 2013 Collins, 2015, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement, BMC Med, 13, 7594, 10.1186/s12916-014-0241-z DeLong, 1988, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, 44, 837, 10.2307/2531595 Boyce, 2013, Evaluation of prediction models for the staging of prostate cancer, BMC Med Inform Decis Mak, 13, 126, 10.1186/1472-6947-13-126 Vickers, 2006, Decision curve analysis: a novel method for evaluating prediction models, Med Decis Mak, 26, 565, 10.1177/0272989X06295361 Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 389, 815, 10.1016/S0140-6736(16)32401-1 Ankerst, 2013, The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator, J Urol, 190, 70, 10.1016/j.juro.2012.12.108 Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 Thompson, 2006, Assessing prostate cancer risk: results from the Prostate Cancer Prevention trial, J Natl Cancer Inst, 98, 529, 10.1093/jnci/djj131 Ankerst, 2018, A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts, Eur Urol, 74, 197, 10.1016/j.eururo.2018.05.003 Sathianathen, 2020, Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the Prostate Imaging Reporting and Data System era: a systematic review and meta-analysis, Eur Urol, 78, 402, 10.1016/j.eururo.2020.03.048 Ptasznik, 2022, High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer, BJU Int, 130, 5, 10.1111/bju.15736 Emmett, 2022, The PRIMARY score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis, J Nucl Med, 10.2967/jnumed.121.263448 Mottet, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 79, 243, 10.1016/j.eururo.2020.09.042